David A. Siegel Mersana Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 937,000 shares of MRSN stock, worth $9.49 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
937,000
Previous 258,200
262.9%
Holding current value
$9.49 Million
Previous $87,000
222.99%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding MRSN
# of Institutions
84Shares Held
94.1MCall Options Held
34.3KPut Options Held
14K-
Nextech Invest Ag12.1MShares$122 Million3.22% of portfolio
-
Nextech Invest, Ltd. Zurich, V812.1MShares$122 Million0.68% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$87.8 Million0.78% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$84.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.68MShares$77.8 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $984M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...